Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Oct 6, 2023; 11(28): 6725-6732
Published online Oct 6, 2023. doi: 10.12998/wjcc.v11.i28.6725
Table 1 Comparison of general information between the two groups (n, mean ± SD)
Group
Gender (Male/Female)
Average age (yr)
Course of disease (wk)
Body mass index (kg/m2)
Control group (40)18/225.70 ± 1.325.6 (3.7-7.9)27.78 ± 2.32
Observation group (40)17/235.69 ± 1.665.5 (3.1-7.7)27.62 ± 2.66
χ2/t value0.0510.030.040.02
P value0.8220.9760.9650.984
Table 2 Comparison of the symptoms and signs scores of the two groups of patients before and after treatment (mean ± SD)
GroupSymptom score
Physical sign score
Nasal itching score
Sneeze score
Runny nose score
Nasal congestion score
Control groupBefore therapy2.14 ± 0.182.08 ± 0.321.84 ± 0.301.79 ± 0.222.13 ± 0.27
After treatment1.76 ± 0.63a1.45 ± 0.26a1.36 ± 0.06a1.37 ± 0.31a1.44 ± 0.23a
Observation groupBefore therapy2.04 ± 0.612.03 ± 0.101.88 ± 0.801.82 ± 0.392.25 ± 0.44
After treatment1.32 ± 0.31a,b1.09 ± 0.26a,b0.92 ± 0.24a,b1.21 ± 0.31a,b1.17 ± 0.37a,b
Table 3 Comparison of serum inflammatory indexes between the two groups (mean ± SD)
Group
IL-6 (ng/L)
TNF-α (pg/L)
IL-10 (ng/L)
sICAM-1 (μg/L)
LTD4 (mg/kg)
Control groupBefore therapy11.78 ± 2.3255.34 ± 7.4026.51 ± 6.3240.78 ± 7.32517.94 ± 23.40
After treatment6.62 ± 1.6622.76 ± 6.6416.55 ± 6.1132.62 ± 5.66206.96 ± 19.24
Observation groupBefore therapy11.78 ± 2.3255.28 ± 7.8026.81 ± 4.3940.93 ± 7.27517.75 ± 10.44
After treatment4.62 ± 0.6619.19 ± 4.7413.41 ± 3.3126.74 ± 3.23158.37 ± 10.37
Table 4 Comparison of adverse reactions between the two groups of patients (mean ± SD)
Group
Dry nose
Dry throat discomfort
Bitter
Minor erosive osmosis of nasal mucosa
Adverse reaction rate
Control group (40)134311 (27.5)
Observation group (40)02103 (7.5)
t value5.541
P value0.019